There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

(HealthDay News) — For patients with chronic obstructive pulmonary disease (COPD), once-daily single-inhaler triple therapy is better for lung function and health-related quality of life than inhaled ...

Please provide your email address to receive an email when new articles are posted on . This analysis spanned from 2016 to 2022. Nearly 50% of patients were initially prescribed LABA/inhaled ...

The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...

Please provide your email address to receive an email when new articles are posted on . There is a need for a nebulized LABA/LAMA formulation in COPD. Bronchodilation, pharmacokinetics and safety of a ...

China NMPA approves GSK’s Trelegy Ellipta for use in adults with uncontrolled asthma: London, UK Saturday, January 24, 2026, 09:00 Hrs [IST] GSK plc announced that China’s Nat ...

PARMA, Italy, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Today, Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group), announced the results of two studies published in The ...

AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic respiratory diseases, today announced the closing of a $21 ...

Results showed budesonide/glycopyrronium/formoterol fumarate 320/28.8/9.6μg met all primary endpoints in both KALOS and LOGOS. Topline data were announced from two ...